Genotyping Market, By Product (Genotyping Instruments, Genotyping Reagents & Kits, and Genotyping Services), By Technology (PCR, Capillary Electrophoresis, Mass Spectrometry, Sequencing, and Microarray), By Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Academic Research, and Agriculture), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Genotype, the genetic constitution of an individual, genotyping is the process of determining differences in the genetic make-up of an individual by examining the individual's DNA sequence using biological assays and comparing it to another individual's sequence or a reference sequence. The genotype determines the hereditary potentials and limitations of an individual from embryonic formation through adulthood.  It identifies small changes in genetic component within individuals. It has broad range of applications in scientific research, medicine, and agriculture. There are three distinct types of genotypes: homozygous dominant, homozygous recessive, and heterozygous. The technological advancement helps in minimize errors and generating effective results and depicted to enhance the penetration rates of these products. The surge in genetic disorders such as Parkinson’s, turner syndrome and Alzheimer’s had a high impact on the market growth. Providing rapid sequencing and early diagnosis helps in the better aid of such disease by healthcare professionals. The global genotyping market accounted for US$ 3.6 billion in 2020 and is estimated to be US$ 21.5 billion by 2030 and is anticipated to register a CAGR of 19.8%.

Drivers: Rising cases of Genetic Diseases

The upsurge in the genetical disorders among individuals across the globe such as Parkinson’s, Alzheimer’s, hemophilia, thalassemia and turner syndrome are driving growth of the global genotyping market. In addition, technological developments in DNA sequencing boost the growth of the target market. Deteriorating prices of DNA sequencing is expected to accelerate growth of the global market over the forecast period.

Restraints: Rising Significance of SNP genotyping

The SNP genotyping is hampering growth of the global growth market. In addition, unfavorable reimbursement policies may also hamper growth of the global market over the forecast period

             Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The global genotyping market is segmented based on product, technology, application, and region.

Based on product, the global genotyping market is segmented into genotyping instruments, genotyping reagents & kits, and genotyping services. In 2015, the reagents & kits segment held the largest market share in terms of revenue. This is mainly attributed due to wide usage rate and the continually surging demand for the genotyping tests. Easy availability and cost-effectiveness of the reagents are anticipated to significantly impact the genotyping market growth. Based on technology, the global target market is bifurcated into PCR, capillary electrophoresis, mass spectrometry, sequencing, and microarray. PCR technology segment is anticipated to be the fastest growing segment over the forecast period. Various developments in the present sequencing technologies have led to drive growth of the global market. Based on application, the global market is bifurcated into diagnostics, drug discovery & development, personalized medicine, academic research, and agriculture. Personalized medicine application segment is anticipated to witness the fastest growth over the forecast period due to growing government support for personalized medicine and the rising adoption of sequencing for genetic mapping. Based on the basis of regions include North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Regional Insights:

The global genotyping market accounted for US$ 3.6 billion in 2020 and is estimated to be US$ 21.5 billion by 2030 and is anticipated to register a CAGR of 19.8%.

On region the global genotyping market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global genotyping market was dominated by North America in 2015 and is expected to maintain its dominance over the forecast period. Rapid advancements in technology and well-established healthcare infrastructure present in this region are the key factors boosting growth of the global market. In addition, growing awareness among people about personalized medicines and the increasing demand for products and services pertaining to genetic testing is also driving growth of the target market in this region. The Asia Pacific region is also projected to grow at the highest growth rate over the forecast period. Introduction of favorable healthcare reforms, growing economic stability, high disposable income, and the presence of untapped market opportunities are the major factors contributing to the regional growth

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global genotyping market report based on product, technology, application, and region.

Global Genotyping Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating the global genotyping market involves GE Healthcare, Affymetrix, Inc., Beckman Coulter, Inc., Agilent Technologies, Inc., Fluidigm Corporation, Illumina, Inc., Life Technologies Corporation, Roche Diagnostics, Qiagen NV, and Vertex Pharmaceuticals. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. In June 2019, Vertex Pharmaceuticals Incorporated announced the approval of symdeko by U.S. Food and Drug Administration (FDA) for the treatment of children of ages 6-11 years suffering from cystic fibrosis. In addition, with this approval, dosage strength of symdeko tablets is also available now.

• GE Healthcare
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Affymetrix Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Beckman Coulter Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Agilent Technologies Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Fluidigm Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Illumina Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Life Technologies Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Roche Diagnostics
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Qiagen NV
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Vertex Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies